Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Asbestos cancer breakthrough

14.11.2003


First-ever blood test for mesothelioma being developed



Researchers at the Pacific Northwest Research Institute (PNRI) have reported the development of a blood test for mesothelioma, a highly aggressive lung cancer caused by asbestos exposure.

A PNRI team led by Dr. Ingegerd Hellstrom, and an Australian team, led by Dr. Bruce Robinson, of the University of Western Australia, conducted the research, which appears in the November 15th issue of Lancet. The new test promises a simple technique for diagnosing and monitoring mesothelioma early in its progress, when therapy is more likely to be successful. Fujirebio Diagnostics, Inc. (FDI) of Malvern, PA, a leading oncology diagnostic company, has acquired an exclusive license from PNRI to develop a commercial test for worldwide distribution.


According to Hellstrom, mesothelioma cells release distinctive molecular markers, SMR (soluble mesothelin-related proteins), into the blood stream. Hellstrom and her colleagues have identified this group of markers and have developed a test to detect them with great specificity.

In blood samples gathered from 273 individuals, researchers found that 84% of those with mesothelioma exhibited high levels of SMR. Only 1.9% of those with other forms of cancer or lung disease had any increased SMR, and patients who were healthy and had not been exposed to asbestos showed no biomarker increase.

"This is a very important breakthrough in the diagnosis and treatment of mesothelioma," Hellstrom explains. "Currently, no blood test exists to detect this cancer and the new biomarker will help doctors see the disease that so far has required much more complicated and expensive tests, and that even then has often gone undetected."

Fujirebio is in the process of initiating the clinical development and commercialization of the mesothelioma test. Dr. Daniel O’Shannessy, FDI’s Chief Scientific Officer, says that this new assay "will provide, for the very first time, a highly effective way of tracking disease progression through noninvasive means."

According to Robinson, from whose patients in Australia the blood samples were drawn, the new research also shows that SMR can be elevated in serum up to several years before actual diagnosis of mesothelioma. "The test may thus prove helpful," Robinson says, "for screening asbestos-exposed individuals for early evidence of mesothelioma."


###
Pacific Northwest Research Institute (PNRI) is a private non-profit biomedical and clinical research laboratory in Seattle, focusing on the prevention and cure of diabetes and cancer. PNRI conducts research in tumor immunology, autoimmune disease, growth factor and metabolic signal transduction pathways, oxidative stress, and large-population screening for diabetes and cancer. The Institute is also participating in a pancreatic islet transplantation research program to treat patients with diabetes. Major emphases of the Hellstrom laboratory at PNRI are on early detection of ovarian, breast, and lung cancers and the development of vaccines for therapeutic purposes. For more information, see www.pnri.org.

Fujirebio Diagnostics, Inc. (FDI), is a premier diagnostics company and the industry leader in Tumor Marker assays specializing in the clinical development, manufacturing and commercialization of in vitro diagnostic products for the management of human disease states with an emphasis in Oncology. The company, formerly known as Centocor Diagnostics, was acquired by Fujirebio, Inc. of Tokyo, Japan in November 1998. FDI utilizes its worldwide distribution network to enable access by physicians and patients to its diagnostic products. For more information on Fujirebio group, visit www.fdi.com.

Contacts:
For PNRI: Rich Murphy
Director of Community Relations, PNRI
206-568-1484
rmurphy@pnri.org

For Fujirebio Diagnostics, Inc.:
Jonathan Morein/Gary Gatyas
Dudnyk Public Relations
267-532-1290/267-532-1244

Rich Murphy | EurekAlert!
Further information:
http://www.pnri.org/

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>